Pertuzumab protects the achilles' heel of trastuzumab--emtansine
- PMID: 24240115
- DOI: 10.1158/1078-0432.CCR-13-2626
Pertuzumab protects the achilles' heel of trastuzumab--emtansine
Abstract
Trastuzumab emtansine (T-DM1) represents a significant advancement in the treatment of HER2(+) breast cancers. Its clinical efficacy however will be limited by the development of therapeutic resistance. In this report, the HER3 ligand neuregulin is shown to mediate T-DM1 resistance, which was overcome by administration of pertuzumab, a steric inhibitor of HER2 dimerization.
©2013 AACR.
Comment on
-
Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.Clin Cancer Res. 2014 Jan 15;20(2):456-68. doi: 10.1158/1078-0432.CCR-13-0358. Epub 2013 Oct 4. Clin Cancer Res. 2014. PMID: 24097864 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous